Who is eligible for clinical trial NCT03043872?

Participants must meet the protocol's inclusion criteria for Small Cell Lung Carcinoma Extensive Disease. The stated age range is 18 Years to 130 Years. Confirm all requirements with the study coordinator.

Does clinical trial NCT03043872 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-07-14

Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN) (NCT03043872)

A Phase III, Randomized, Multicenter,Open-Label, Comparative Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for the First-Line Treatment in Patients With Extensive Disease Small-Cell Lung Cancer (SCLC) (CASPIAN)

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: AstraZeneca

🩺 Plain-English Summary (8th-Grade Level)

This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of combining durvalumab ± tremelimumab with platinum based chemotherapy (EP) followed by durvalumab ± tremelimumab maintenance therapy versus EP alone as first-line treatment in patients with extensive-stage small-cell lung cancer

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (5 items) and avoid the listed exclusions (6 items).

Location: Research Site — Birmingham, Alabama

Age range: 18 Years to 130 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Histologically or cytologically documented extensive disease. Brain metastases; must be asymptomatic or treated and stable off steroids and anti-convulsants for at least 1 month prior to study treatment.
Suitable to receive a platinum-based chemotherapy regimen as 1st line treatment.
Life expectancy ≥12 weeks at Day 1.
ECOG 0 or 1 at enrolment.
No prior exposure to immune-mediated therapy excluding therapeutic anticancer vaccines.

Usually NOT eligible if any of the following apply:

Exclusion criteria:
Any history of radiotherapy to the chest prior to systemic therapy or planned consolidation chest radiation therapy (except paliative care outside of the chest).
Paraneoplastic syndrome of autoimmune nature, requiring systemic treatment or clinical symptomatology suggesting worsening of PNS
Active infection including tuberculosis, HIV, hepatitis B anc C
Active or prior documented autoimmune or inflammatory disorders
Uncontrolled intercurrent illness, including but not limited to interstitial lung disease.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (207 Sites)

Showing the first 25 of 207 sites.

Research Site — Birmingham, Alabama
Research Site — Scottsdale, Arizona
Research Site — Rogers, Arkansas
Research Site — Santa Monica, California
Research Site — New Haven, Connecticut
Research Site — Athens, Georgia
Research Site — Fort Wayne, Indiana
Research Site — Muncie, Indiana
Research Site — Leawood, Kansas
Research Site — Wichita, Kansas
Research Site — Paducah, Kentucky
Research Site — Grand Rapids, Michigan
Research Site — Mineola, New York
Research Site — Cleveland, Ohio
Research Site — Columbus, Ohio
Research Site — Harrisburg, Pennsylvania
Research Site — Sioux Falls, South Dakota
Research Site — Nashville, Tennessee
Research Site — Kennewick, Washington
Research Site — Buenos Aires,
Research Site — Ciudad de Buenos Aires,
Research Site — Mar del Plata,
Research Site — Rosario,
Research Site — San Miguel de Tucumán,
Research Site — Linz,

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

Explore by condition: All Small Cell Lung Carcinoma Extensive Disease clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Review the official NIH record below to find the coordinating site.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗